Confronto
Bremelanotide vs. Selank
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
189691-06-3
129954-34-3
Peso molecolare
1025.18 g/mol
751.85 g/mol
Emivita
2.7 h
0.3 h
Sequenza
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHThr-Lys-Pro-Arg-Pro-Gly-ProMeccanismo d'azione
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Selank
Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
5
4
di cui sull'uomo
5
2
Effetti registrati
3
3
Contraddizioni aperte
1
1
Eventi avversi documentati
2
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Bremelanotide and Selank?
- Bremelanotide is classified as "Ricerca (altro)", while Selank is classified as "Ricerca (altro)". Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Bremelanotide or Selank?
- The highest available evidence level is "RCT sull'uomo" for Bremelanotide and "Studio sull'uomo" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Bremelanotide and Selank in Germany and the United States?
- Germania: Bremelanotide — Non approvato, Selank — Non approvato. Stati Uniti: Bremelanotide — Su prescrizione, Selank — Non approvato. These are factual summaries with source and review date on the individual pages.